Proactive Management of Gestational Hypertension in a Patient With Uterine Fibroids: A Case Report
Abstract
The coexistence of uterine fibroids and gestational hypertension (GH) presents a high‐risk obstetric scenario associated with adverse maternal‐fetal outcomes. We present the case of a 27‐year‐old primigravida diagnosed with a 22 × 28 mm anterior uterine fibroid at 8 weeks' gestation, which enlarged to 52 × 48 mm by 29 weeks. At 21 weeks' gestation, she developed new‐onset GH (blood pressure 150/98 mmHg) without proteinuria. Her management included prophylactic low‐dose aspirin (75 mg daily), methyldopa (250 mg twice daily), and structured home blood pressure monitoring. When her blood pressure rose to 155/100 mmHg at 34 weeks, the methyldopa dosage was increased to three times daily, which successfully restored control. Following induction of labor at 40 weeks, the patient had an uncomplicated vaginal delivery of a healthy 3.3 kg neonate with an APGAR score of 9. The postpartum course was unremarkable, and the fibroid regressed significantly. This case illustrated that a proactive, guideline‐based strategy uniting early prophylaxis, adaptive pharmacotherapy guided by home monitoring, and anticipatory care can successfully navigate the compounded risks of this clinical dyad, leading to a favorable outcome.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.